{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:23:51Z","timestamp":1790054631401,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clim.2017.09.004","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T17:16:53Z","timestamp":1504545413000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["HLA class Ia and Ib molecules and FOXP3+ TILs in relation to the prognosis of malignant melanoma patients"],"prefix":"10.1016","volume":"183","author":[{"given":"Wenna Nascimento","family":"Melsted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Lindholm","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Lock-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nille","family":"Behrendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Ole","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bzorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scheike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Vauvert F.","family":"Hviid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2017.09.004_bb0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.immunol.16.1.323","article-title":"Mechanisms of MHC class I - restricted antigen processing","volume":"16","author":"Pamer","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/humupd\/dmr043","article-title":"Human leucocyte antigen class Ib molecules in pregnancy success and early pregnancy loss","volume":"18","author":"Dahl","year":"2012","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.clim.2017.09.004_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/scbi.2001.0404","article-title":"HLA class I antigen abnormalities and immune escape by malignant cells","volume":"12","author":"Seliger","year":"2002","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.clim.2017.09.004_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1034\/j.1600-065X.2002.18808.x","article-title":"Antigenicity and immunogenicity of Melan-A\/Mart-1 derived peptides as targets for tumor reactive CTL in human melanoma","volume":"188","author":"Romero","year":"2002","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2017.09.004_bb0025","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.21873\/anticanres.11144","article-title":"Cancer immunology and immunotherapy","volume":"36","author":"Sukari","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.clim.2017.09.004_bb0030","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.09.004_bb0035","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective Braf(v600e) inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2017.09.004_bb0040","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6829283","article-title":"The pathophysiological impact of HLA class Ia and HLA-G expression and regulatory T cells in malignant melanoma: a review","author":"Johansen","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clim.2017.09.004_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0165-0378(99)00037-6","article-title":"HLA-G expression in human melanoma cells: protection from NK cytolysis","volume":"43","author":"Cabestre","year":"1999","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0050","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1016\/S1470-2045(11)70155-3","article-title":"Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?","volume":"13","author":"Jacobs","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2017.09.004_bb0055","first-page":"3930","article-title":"Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens","volume":"44","author":"Ruiter","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2017.09.004_bb0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ijc.2910360106","article-title":"Phenotypic dynamics of tumor progression in human malignant melanoma","volume":"36","author":"Brocker","year":"1985","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.clim.2017.09.004_bb0065","first-page":"35","article-title":"MHC antigens in human melanomas","volume":"2","author":"Ruiter","year":"1991","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.clim.2017.09.004_bb0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0198-8859(02)00389-0","article-title":"HLA expression in uveal melanoma: there is no rule without some exception","volume":"63","author":"Jager","year":"2002","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0075","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1167\/iovs.11-9280","article-title":"Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanomatumor-infiltrating lymphocytes in uveal melanoma","volume":"53","author":"Bronkhorst","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.clim.2017.09.004_bb0080","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/intimm\/11.8.1351","article-title":"HLA-G-mediated inhibition of antigen-specific cytotoxic t lymphocytes","volume":"11","author":"Le Gal","year":"1999","journal-title":"Int. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0085","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.274.5288.792","article-title":"Protection from natural killer cell-mediated lysis by HLA-G expression on target cells","volume":"274","author":"Pazmany","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.clim.2017.09.004_bb0090","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2006-11-057125","article-title":"HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation","volume":"110","author":"Feger","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.09.004_bb0095","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1182\/blood-2007-04-083139","article-title":"CD3(+)CD4(low) and CD3(+)CD8(low) are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance","volume":"110","author":"Naji","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.09.004_bb0100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1634\/stemcells.2007-0554","article-title":"Human leukocyte antigen-g5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4(+)CD25(high)FOXP3(+) regulatory T cells","volume":"26","author":"Selmani","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.clim.2017.09.004_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.semcancer.2007.07.003","article-title":"Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses","volume":"17","author":"Rouas-Freiss","year":"2007","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.clim.2017.09.004_bb0110","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1073\/pnas.95.8.4510","article-title":"HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance","volume":"95","author":"Paul","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2017.09.004_bb0115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.11456","article-title":"Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype","volume":"108","author":"El Ibrahim","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.clim.2017.09.004_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002371-200401000-00007","article-title":"High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma","volume":"27","author":"Hofbauer","year":"2004","journal-title":"J. Immunother."},{"key":"10.1016\/j.clim.2017.09.004_bb0125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000150602","article-title":"Quantitative HLA-G expression in metastasising and non-metastasising primary thin cutaneous melanomas","volume":"217","author":"Bezuhly","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.clim.2017.09.004_bb0130","first-page":"1115","article-title":"Utility of tumour-infiltrating CD25(+)FOXP3(+) regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma","volume":"18","author":"Miracco","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.clim.2017.09.004_bb0135","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/1471-2407-14-486","article-title":"Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study","volume":"14","author":"Reimers","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clim.2017.09.004_bb0140","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/bjc.2013.696","article-title":"Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients","volume":"110","author":"Zeestraten","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2017.09.004_bb0145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-013-2752-2","article-title":"Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients","volume":"142","author":"de Kruijf","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.clim.2017.09.004_bb0150","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","article-title":"Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5","volume":"97","author":"Tsukahara","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2017.09.004_bb0155","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1349-7006.2007.00558.x","article-title":"HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer","volume":"98","author":"Kikuchi","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2017.09.004_bb0160","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/sj.bjc.6604715","article-title":"Downregulation of HLA class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma","volume":"99","author":"Mizukami","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2017.09.004_bb0165","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.4049\/jimmunol.177.5.3100","article-title":"Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells","volume":"177","author":"Derre","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.12164","article-title":"A melanoma immune response signature including human leukocyte antigen-e","volume":"27","author":"Tremante","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.clim.2017.09.004_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0198-8859(02)00821-2","article-title":"Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules","volume":"64","author":"Menier","year":"2003","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0180","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1399-0039.2012.01922.x","article-title":"Reassessment of HLA-G isoform specificity of MEM-G\/9 and 4H84 monoclonal antibodies","volume":"80","author":"Zhao","year":"2012","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.clim.2017.09.004_bb0185","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1369\/jhc.6A7119.2007","article-title":"Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4(+) CD25(+) T cells in normal skin and inflammatory dermatoses","volume":"55","author":"de Boer","year":"2007","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.clim.2017.09.004_bb0190","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1349-7006.2011.01951.x","article-title":"Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells","volume":"102","author":"Du","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2017.09.004_bb0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ni746","article-title":"Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection","volume":"3","author":"Kelly","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0205","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ni1102-999","article-title":"Natural selection of tumor variants in the generation of \"tumor escape\" phenotypes","volume":"3","author":"Khong","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2017.09.004_bb0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0167-5699(96)10075-X","article-title":"Implications for immunosurveillance of altered HLA class I phenotypes in human tumours","volume":"18","author":"Garrido","year":"1997","journal-title":"Immunol. Today"},{"key":"10.1016\/j.clim.2017.09.004_bb0215","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2017.09.004_bb0220","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/annonc\/mds229","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Dummer","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2017.09.004_bb0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0167-5699(95)80033-6","article-title":"Loss of HLA class-I antigens by melanoma-cells - molecular mechanisms, functional-significance and clinical relevance","volume":"16","author":"Ferrone","year":"1995","journal-title":"Immunol. Today"},{"key":"10.1016\/j.clim.2017.09.004_bb0230","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00251-008-0303-5","article-title":"Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy","volume":"60","author":"Carretero","year":"2008","journal-title":"Immunogenetics"},{"key":"10.1016\/j.clim.2017.09.004_bb0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.cji.0000199193.29048.56","article-title":"Immune suppression in the tumor microenvironment","volume":"29","author":"Gajewski","year":"2006","journal-title":"J. Immunother."},{"key":"10.1016\/j.clim.2017.09.004_bb0240","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2002.08.072","article-title":"Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome","volume":"20","author":"Sosman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2017.09.004_bb0245","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00262-006-0226-7","article-title":"HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination","volume":"56","author":"Cabrera","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2017.09.004_bb0250","first-page":"274","article-title":"HLA class I expression in metastatic melanoma lesions determines the progression\/regression of the metastases in response to immunotherapy","volume":"71","author":"Carretero","year":"2008","journal-title":"Tissue Antigens"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617300414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617300414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:58:55Z","timestamp":1761494335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661617300414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":50,"alternative-id":["S1521661617300414"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.09.004","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HLA class Ia and Ib molecules and FOXP3+ TILs in relation to the prognosis of malignant melanoma patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}